{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-236770","form_type":"8-K","ticker":null,"cik":"0001183765","company_name":"Molecular Templates, Inc.","filed_at":"2024-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.862628+00:00","generated_at":"2026-05-30T15:13:58.613658+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Molecular Templates board approves dissolution, expects no value for shareholders","bullets":["Board unanimously approved liquidation and wind-up subject to stockholder approval; no viable strategic alternatives found.","Company does not expect stockholders to receive any value for their shares in dissolution.","Reduction in force of substantially all employees; Phase 1 studies for MT-6402 and MT-8421 to be wound down.","Discussions with FDA on MT-0169 for autoimmune indications to continue; Rock Creek Advisors engaged.","Negligible costs expected for reduction in force; substantially complete in October 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-236770","json":"https://secwatch.observer/filing/0001193125-24-236770.json","markdown":"https://secwatch.observer/filing/0001193125-24-236770.md","text":"https://secwatch.observer/filing/0001193125-24-236770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524236770/0001193125-24-236770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524236770/d840872d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T15:13:58.613658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"945884a68a8916cfee94b994231eb7071f59f7e5","claim":"Molecular Templates, Inc. announced a restructuring with charges of negligible amount affecting substantially all of the Company’s employees (reduction in force of substantially all of the Company’s employees, other than key members of management).","evidence_excerpt":"On October 11, 2024, the Board approved a reduction in force of substantially all of the Company’s employees, other than key members of management necessary to implement the wind up and support the efforts to maximize the value of the business and its assets. The Company estimates that it will incur a negligible amount of costs in connection with the reduction in force, primarily consisting of legal fees and other related termination costs.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524236770/0001193125-24-236770-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"negligible amount"},{"label":"Affected area","value":"substantially all of the Company’s employees"},{"label":"Headcount","value":"reduction in force of substantially all of the Company’s employees, other than key members of management"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}